格隆汇6月30日丨华昊中天医药-B(02563.HK)公告,截至2024年12月31日止年度,集团收入为人民币71.9百万元,同比增加7.9%。该变动乃主要由于公司的产品(优替德隆注射液)市场渗透提高导致销售收入增长。公司的亏损由2023年的人民币189.6百万元缩减45.8百万元至2024年的人民币143.8百万元。集团的毛利由截至2023年12月31日止年度的人民币46.8百万元增加30.5%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.